Newsroom

GREENBROOK TMS COMPLETES C$30 MILLION BOUGHT DEAL PUBLIC OFFERING AND CONCURRENT PRIVATE PLACEMENT

May 17, 2019 – Toronto, ON – Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States, announced today that it has completed its previously announced bought deal public offering and concurrent private placement (the “Offerings”) for total gross proceeds of C$30,579,250.

The Offerings were both completed on a bought deal basis by a syndicate of underwriters led by Bloom Burton Securities Inc., and that included Clarus Securities Inc., Desjardins Capital Markets and GMP Securities L.P. (collectively, the “Underwriters”). The public offering of 4,025,000 common shares (the “Common Shares”) at a price of C$3.25 per Common Share (the “Issue Price”), for gross proceeds of C$13,081,250 included 525,000 Common Shares issued pursuant to the full exercise of the Underwriters’ over-allotment option. The concurrent bought deal private placement of 5,384,000 Common Shares were purchased by 1315 Capital II, LP at the Issue Price, for gross proceeds of C$17,498,000.

The Company intends to use the net proceeds from the Offerings for the development of new TMS centers, for potential acquisitions and for working capital and general corporate purposes.

The securities offered have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Read More  >


GREENBROOK TMS CONTINUES EXECUTION OF GROWTH STRATEGY AND REPORTS FIRST QUARTER FINANCIAL RESULTS

May 9, 2019 – Toronto, ON – Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”), today announced its first quarter 2019 operational and financial results. For more information, please refer to Management’s Discussion & Analysis of Financial Condition and Results of Operations (“MD&A”) and the unaudited condensed interim consolidated financial statements of the Company for the three-months ended March 31, 2019 and 2018. These documents will be available on the Company’s website at www.greenbrooktms.com and under the Company’s SEDAR profile at www.sedar.com. All values in this news release are in United States dollars, unless otherwise stated.


Bill Leonard, President and Chief Executive Officer of Greenbrook commented:
“We are pleased with our results this quarter as we continue to experience strong year-over-year growth rates both with our newly established centers as well as with our existing footprint. With more than 70 centers now in our network we are meeting our development objectives and with the recent financing we have the opportunity to accelerate that growth even faster.”

Read More  >


GREENBROOK TMS ANNOUNCES EXPANSION INTO MICHIGAN

May 9, 2019 – Toronto, ON – Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States, is pleased to announce the expansion of its TMS Center network into the State of Michigan. The Company will begin operating a TMS Center in the Detroit, Michigan region.


Greenbrook expects to open additional TMS Centers in Michigan as part of its regional development strategy.

Read More  >


GREENBROOK TMS ANNOUNCES C$29 MILLION BOUGHT DEAL PUBLIC OFFERING AND CONCURRENT PRIVATE PLACEMENT

April 29, 2019 – Toronto, ON – Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States, announced today that it has entered into an agreement with a syndicate of underwriters led by Bloom Burton Securities Inc., and including Clarus Securities Inc., Desjardins Securities Inc. and GMP Securities L.P. (collectively, the “Underwriters”), under which the Underwriters have agreed to buy, on a bought deal public offering basis, 3,500,000 common shares of the Company (the “Shares”) at a price of C$3.25 per Share (the “Offering Price”) for aggregate gross proceeds of approximately C$11,375,000 (the “Public Offering”). Concurrent with the Public Offering, the Underwriters have also agreed to buy, on a bought deal private placement basis, 5,384,000 Shares at the Offering Price for aggregate gross proceeds of approximately C$17,498,000 (the “Private Placement” and, together with the Public Offering, the “Offerings”).

In connection with the Public Offering, the Company has granted the Underwriters an over-allotment option, exercisable in whole or in part at any one time up to 30 days following closing of the Public Offering, to purchase up to an additional 525,000Shares at the Offering Price which, if exercised in full, would increase the gross proceeds of the Public Offering to approximately C$13,081,250.

The Offerings are expected to close on or about May 17, 2019, subject to certain customary conditions, including approval of the Toronto Stock Exchange. The closing of the Public Offering will be conditional upon closing of the Private Placement and closing of the Private Placement will be conditional upon closing of the Public Offering.

The Company intends to use the net proceeds from the Offerings to open new Greenbrook TMS centers, for potential acquisitions, and for working capital and general corporate purposes.The Shares that form part of the Public Offering will be offered in all provinces of Canada, except Quebec, by way of a short form prospectus and on a private placement basis in the United States, and internationally as permitted. The preliminary short form prospectus is intended to be filed on or before May 3, in each of the provinces of Canada, except Quebec.

The securities offered have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Read More  >


GREENBROOK TMS TO PRESENT AT 2019 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE

April 19, 2019 – Toronto, ON – Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States, is pleased to announce that it will participate and present at the Bloom Burton & Co. Healthcare Conference in Toronto on April 30th to May 1st, 2019.

Mr. Bill Leonard, President and Chief Executive Officer will present a corporate overview and the Company’s growth plans for 2019 and beyond.

Greenbrook’s presentation details are:

When: Wednesday May 1st, 2019
Time: 10:30 a.m. Eastern time
Where: Metro Toronto Convention Centre, 255 Front Street West, Toronto, Ontario

Read More  >


GREENBROOK TMS ANNOUNCES DATES FOR ITS FIRST QUARTER 2019 FINANCIAL RESULTS

April 9, 2019 – Toronto, ON – Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”) will release its 2019 first quarter operational and financial results after market hours on May 9, 2019.

First Quarter 2019 Conference Call Details

Bill Leonard, President and Chief Executive Officer and Erns Loubser, Chief Financial Officer, will host a conference call at 10:00 a.m. (Eastern Time) on May 10, 2019 to discuss the financial results for the quarter.

For more information or to listen to the call via webcast, please visit:
https://www.greenbrooktms.com/investors/events.htm 

Read More  >


GREENBROOK TMS SELECTED BY KAISER PERMANENTE AS PROVIDER OF TMS THERAPY SERVICES IN THE MID-ATLANTIC STATES

April 2, 2019 – Toronto, ON – Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States, is pleased to announce that it has entered into an agreement with Kaiser Foundation Health Plan of the Mid-Atlantic States, Inc. (“Kaiser”) pursuant to which Greenbrook and its affiliates will provide TMS therapy services to Kaiser members in Maryland, Virginia and the District of Columbia.

Kaiser selected Greenbook based on its patient-focused customer service model, its clinical leadership and its ability to serve Kaiser’s geographically diverse member base.  Pursuant to the agreement, Kaiser’s more than 765,000 members will initially have access to TMS therapy at 19 Greenbrook TMS Center locations located in Northern Virginia and Suburban Maryland.

“We applaud Kaiser on extending access to TMS therapy to its members and are pleased that Greenbrook was selected as Kaiser’s TMS therapy provider in the Mid-Atlantic States,” stated Bill Leonard, President and Chief Executive Officer of Greenbrook. Continued Leonard, “We are excited to provide Kaiser’s members and physicians with access to high-quality, customer centric TMS therapy services at Greenbrook’s TMS Center locations”.  

Read More  >


GREENBROOK TMS REPORTS FOURTH QUARTER AND YEAR END 2018 FINANCIAL RESULTS

March 27, 2019 – Toronto, ON – Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”) today announced its fourth quarter (“Q4 2018”) and year-end 2018 (“Fiscal 2018”) operational and financial results. For more information, please refer to the Company’s audited consolidated financial statements, including the notes thereto, for the fiscal years ended December 31, 2018 and 2017 and related Management’s Discussion & Analysis of Financial Condition and Results of Operations (“MD&A”). These documents will be available on the Company’s website at www.greenbrooktms.com and under the Company’s SEDAR profile at www.sedar.com. All values in this news release are in United States dollars unless otherwise stated.

Bill Leonard, President and Chief Executive Officer of Greenbrook commented:

“We are very pleased with our annual results and strong fourth quarter performance. On top of solid growth in revenue and regional operating income, we have continued to execute our growth strategy, significantly increasing our active footprint, including five new management regions which will provide the foundation for future growth”.

Read More  >


GREENBROOK TMS ANNOUNCES DATES FOR ITS FOURTH QUARTER AND YEAR END 2018 FINANCIAL RESULTS

February 26, 2019 – Toronto, ON – Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”) will release its 2018 fourth quarter and year end operational and financial results after market hours on March 27, 2019. 

Fourth Quarter 2018 Conference Call Details
Bill Leonard, President and Chief Executive Officer and Erns Loubser, Chief Financial Officer, will host a conference call at 10:00 a.m. (Eastern Time) on March 28, 2019 to discuss the financial results for the quarter and year end.

Webcast:
For more information or to listen to the call via webcast, please visit:
https://www.greenbrooktms.com/investors/events.htm               

Read More  >


GREENBROOK TMS ANNOUNCES EXPANSION INTO TAMPA-ST. PETERSBURG FLORIDA

January 9, 2019 – Toronto, ON – Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States, is pleased to announce the expansion of its TMS Center network into the Tampa-St. Petersburg Metropolitan region. The Company will begin operating three TMS Centers in the Tampa-St. Petersburg, Florida region.   

Greenbrook expects to open additional TMS Centers in the Tampa-St. Petersburg Metropolitan area as part of its regional development strategy.

Read More  >


GREENBROOK TMS ANNOUNCES EXPANSION INTO CLEVELAND OHIO

December 28, 2018 – Toronto, ON – Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States, is pleased to announce the expansion of its TMS Center network into the Cleveland Metropolitan region. The Company will begin operating two TMS Centers in Cleveland, Ohio.

Greenbrook expects to open additional TMS Centers in the Cleveland Metropolitan area as part of its regional development strategy.

Read More  >


GREENBROOK TMS CONTINUES SUCCESSFUL EXECUTION OF GROWTH STRATEGY AND REPORTS THIRD QUARTER FINANCIAL RESULTS

November 12, 2018 – Toronto, ON – Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”) today announced its third quarter 2018 operational and financial results. For more information, please refer to Management’s Discussion and Analysis of Financial Condition and Results of operations (“MD&A”) and the unaudited condensed interim consolidated financial statements for the three- and nine-month periods ended September 30, 2018 and 2017. These documents will be available under the Company’s SEDAR profile at www.sedar.com. All values in this news release are in United States dollars unless otherwise stated. 

Bill Leonard, President and Chief Executive Officer of Greenbrook commented: 
“We are very pleased with our results this quarter. In addition to a strong performance from our existing centers we have continued to execute our growth strategy. In this quarter alone, we expanded our TMS Center network with 5 new centers. Subsequently, we opened an additional 3 regions bringing our total to 48 centers across 8 management regions.”

Read More  >


GREENBROOK TMS CENTERS BEGIN TO TREAT OBSESSIVE COMPULSIVE DISORDER WITH TMS THERAPY

November 8, 2018 – Toronto, ON – Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States for the treatment of Major Depressive Disorder (“MDD”), is pleased to announce that its TMS Centers will begin to offer treatment for Obsessive Compulsive Disorder (“OCD”). The treatment, which will be rolled out throughout the Company’s TMS Center network, delivers targeted magnetic pulses into the region of the brain implicated in OCD. As with all other TMS therapy provided at Greenbrook’s TMS Centers, this outpatient, office-based treatment is FDA-cleared, safe and non-invasive. Patients can resume daily activities immediately following a treatment session. 

OCD is a condition which causes intrusive and recurring obsessions and/or compulsions that interfere with a person’s daily activities and quality of life. Over 2 million adults in the United States are diagnosed with OCD each year. Conventional OCD treatments are only effective in about 50% of cases. 

Dr. Geoffrey Grammer, Chief Medical Officer of the Company stated: “The launch of this OCD treatment demonstrates our commitment to utilizing the latest developments in Transcranial Magnetic Stimulation to offer our patients the very best care possible. The H7 coil system developed by Brainsway provides us the new capability to treat areas of the brain involved in OCD and provide patients a truly novel approach to symptom relief.”

Read More  >


GREENBROOK TMS ANNOUNCES EXPANSION INTO HOUSTON TEXAS

October 31, 2018 – Toronto, ON – Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States for the treatment of Major Depressive Disorder (“MDD”), is pleased to announce the expansion of its TMS Center network into the Greater Houston region. As part of Greenbrook’s continued expansion into the State of Texas, the Company will begin operating a TMS Center in Sugar Land, Texas under the clinical leadership of Dr. Kimberly Cress, a current member of the Board of Directors of the Clinical TMS Society, and a leader in the field of TMS and neuromodulation.

Greenbrook expects to open additional TMS Centers in the Greater Houston area as part of its regional development strategy.

“I am thrilled for this opportunity to join Greenbrook TMS as they continue their expansion in Texas. As an experienced TMS provider since 2010, I look forward to working with Greenbrook, its physician partners and staff to continue to increase awareness of TMS and to provide more individuals with access to this potentially life changing therapy”, said Dr. Cress. Dr. Cress will serve as a Regional Medical Director of the Company.

Read More  >


GREENBROOK TMS ANNOUNCES DATES FOR ITS THIRD QUARTER 2018 RESULTS

October 29, 2018 – Toronto, ON – Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the“Company”) will release its third quarter 2018 operational and financial results after market hours on November 12, 2018.

Bill Leonard, President and Chief Executive Officer, and Erns Loubser, Chief Financial Officer, will host a conference call at 10:00 a.m. (Eastern Time) on November 13, 2018 to discuss the financial results for the quarter. 

Read More  >


GREENBROOK TMS ANNOUNCES EXPANSION INTO AUSTIN TEXAS

October 23, 2018 – Toronto, ON – Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States for the treatment of Major Depressive Disorder (“MDD”), is pleased to announce the expansion of its TMS Center network into the Austin Metropolitan region. The Company’s subsidiary, Greenbrook TMS Austin Central LLC (“Greenbrook TMS Austin”), will begin operating a TMS Center in Central Austin, Texas. Greenbrook TMS Austin marks the initial expansion of Greenbrook’s TMS Center network throughout the State of Texas.

Read More  >


GREENBROOK TMS ANNOUNCES EXPANSION INTO CONNECTICUT

October 16, 2018 – Toronto, ON – Greenbrook TMS Inc. (“Greenbrook” or the “Company”) (TSX:GTMS), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States for the treatment of Major Depressive Disorder (“MDD”), is pleased to announce the expansion of its TMS Center network into the State of Connecticut. The Company’s subsidiary, Greenbrook TMS Connecticut LLC (“Greenbrook TMS Connecticut”), will begin operating two TMS Centers in Westport and Milford, Connecticut under the clinical leadership of Dr. Serena-Lynn Brown.

Greenbrook expects to partner with other physicians to open additional TMS Centers in Connecticut as part of its regional development strategy.

“We are very pleased to be partnering with Greenbrook as they begin their expansion in the Connecticut region. With this partnership we hope to promote increased awareness, affordability, and quality of care for TMS therapy patients in Connecticut”, said Dr. Brown. Dr. Brown will serve as Medical Director of Greenbrook TMS Connecticut.

Read More  >


GREENBROOK TMS ANNOUNCES LISTING ON THE TORONTO STOCK EXCHANGE

October 3, 2018 – Toronto, ON – Greenbrook TMS Inc., a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States for the treatment of Major Depressive Disorder (“MDD”), today announced that the Toronto Stock Exchange (“TSX”) has accepted the Company’s listing application to list its common shares on the TSX. The Company’s common shares will begin trading at the opening of markets today under the symbol “GTMS”.

Additional information in respect of Greenbrook’s business is available in its (final) long form prospectus dated September 27, 2018,, available under the Company’s SEDAR profile at www.sedar.com.

Read More  >


GREENBROOK TMS ANNOUNCES FILING OF FINAL PROSPECTUS

September 27, 2018 – Toronto, ON – Greenbrook TMS Inc., a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States for the treatment of Major Depressive Disorder (“MDD”), today announced that it has filed and obtained a receipt for its final prospectus from the applicable Canadian securities regulatory authorities.

The Prospectus qualifies the distribution of 10,000,000 common shares of Greenbrook issuable upon exercise or deemed exercise of 10,000,000 special warrants (the “Special Warrants”). The Special Warrants were issued to purchasers in March and June 2018 at a price of US$2.00 per Special Warrant, pursuant to prospectus exemptions under applicable securities legislation, for aggregate gross proceeds of US$20 million.

Read More  >